Flaget Memorial Hospital | |
4305 New Shepherdsville Road, Bardstown, Kentucky 40004 | |
(502) 350-5000 | |
Name | Flaget Memorial Hospital |
---|---|
Type | Acute Care Hospital |
Location | 4305 New Shepherdsville Road, Bardstown, Kentucky |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 180025 |
NPI Number | 1871588772 |
Organization Name | FLAGET HEALTHCARE, INC |
Doing Business As | FLAGET MEMORIAL HOSPITAL |
Address | 4305 New Shepherdsville Rd, Bardstown, KY 40004 |
Hospital Type | General Acute Care Hospital |
Phone Number | 502-350-5000 |
News Archive
Antibiotic resistance is a grand challenge of the 21st century. According to the U.S. Centers for Disease Control and Prevention, antibiotic resistance rates are increasing globally, with an estimated 35,000 related deaths per year in the United States in 2019, compared to 23,000 in 2013.
Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.
Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.
In a research article published in this week's PLoS Medicine, Ann Killary (from the University of Texas M. D. Anderson Cancer Center) and colleagues describe a new gene called DEAR1 that is genetically altered by mutation and deletion in breast tumors, and that may provide a new breast cancer prognostic marker.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 8 days ago
Able to receive lab results electronically | No |
Able to track patients' lab results, tests, and referrals electronically between visits | No |
News Archive
Antibiotic resistance is a grand challenge of the 21st century. According to the U.S. Centers for Disease Control and Prevention, antibiotic resistance rates are increasing globally, with an estimated 35,000 related deaths per year in the United States in 2019, compared to 23,000 in 2013.
Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.
Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.
In a research article published in this week's PLoS Medicine, Ann Killary (from the University of Texas M. D. Anderson Cancer Center) and colleagues describe a new gene called DEAR1 that is genetically altered by mutation and deletion in breast tumors, and that may provide a new breast cancer prognostic marker.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
› Verified 8 days ago
Flaget Memorial Hospital Acute Care Hospital Location: 4305 New Shepherdsville Road, Bardstown, Kentucky 40004 Phone: (502) 350-5000 |